Abciximab readministration: Results of the ReoPro Readministration Registry

James E. Tcheng, Dean J. Kereiakes, A. Michael Lincoff, Barry S. George, Neal S. Kleiman, David C. Sane, Douglas B. Cines, Robert E. Jordan, Mary Ann Mascelli, Mary Ann Langrall, Lakshmi Damaraju, Allen Schantz, Mark B. Effron, Gregory A. Braden

Research output: Contribution to journalArticlepeer-review

138 Scopus citations


Background - Platelet glycoprotein IIb/IIIa blockade with abciximab (ReoPro) improves the clinical outcomes of percutaneous coronary intervention. This registry was conducted to characterize the effects of repeated administration of abciximab during intervention. Methods and Results - We recruited 500 consecutive patients at 22 centers in the United States who were receiving abciximab for at least a second time during percutaneous coronary intervention. Safety was measured as the incidence of hypersensitivity reactions, major bleeding, and thrombocytopenia. Efficacy was assessed as event-free clinical success. Human antichimeric antibody (HACA) responses were also characterized. There were no cases of hypersensitivity (95% upper confidence bound, 0.3%), major bleeding, or death. Clinical success was 94.4%. Thrombocytopenia occurred in 23 patients (4.6%; 95% CI, 2.8% to 6.4%), including 12 (2.4%; 95% CI, 1.1% to 3.7%) who developed profound thrombocytopenia (<20×109 cells/L). In 2 patients (0.4%), profound thrombocytopenia did not develop until after hospital discharge; in 4 (0.8%), profound thrombocytopenia recurred despite platelet transfusion. Before a first readministration, a positive HACA titer was present in 22 of 454 patients (4.8%); after a first readministration, an additional 82 of 432 (19.0%) became HACA-positive. HACA did not neutralize the in vitro inhibition of platelet aggregation by abciximab or correlate with clinical events. Conclusions - The results, including overall rates of thrombocytopenia, were consistent with randomized clinical trials of first abciximab treatment. However, there was a shift from mild to profound thrombocytopenia, and cases of delayed presentation and of recurrent thrombocytopenia were seen. These findings suggest that indications and guidelines for first-time use apply to retreatment, particularly the systematic monitoring for thrombocytopenia.

Original languageEnglish (US)
Pages (from-to)870-875
Number of pages6
Issue number8
StatePublished - Aug 21 2001


  • Angioplasty
  • Pharmacodynamics
  • Platelet aggregation inhibitors
  • Thrombocytopenia

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Abciximab readministration: Results of the ReoPro Readministration Registry'. Together they form a unique fingerprint.

Cite this